High PTGS2 expression in post neoadjuvant chemotherapy treated oesophageal adenocarcinoma is associated with improved survival: a population-based cohort study

    Research output: Contribution to journalArticle

    Early online date

    Standard

    Harvard

    APA

    Vancouver

    Author

    Bibtex

    @article{e2bd61ad181446128b6b16f3c64da3ae,
    title = "High PTGS2 expression in post neoadjuvant chemotherapy treated oesophageal adenocarcinoma is associated with improved survival: a population-based cohort study",
    abstract = "AimsHigh prostaglandin endoperoxide synthase‐2 (PTGS2) enzyme expression in oesophageal adenocarcinoma has been shown to independently predict poor prognosis, however evidence is inconsistent. We investigated the association between PTGS2 expression and prognosis in patients with oesophageal adenocarcinoma.Methods and resultsA cohort of 135 patients with oesophageal adenocarcinoma who received neoadjuvant chemotherapy and surgery from 2004 to 2012 was identified in the Northern Ireland Cancer Centre. Tissue microarrays were created in the Northern Ireland Biobank, sampling triplicate cores from each tumour. Immunohistochemical PTGS2 expression was scored by two independent assessors with intensity and proportion of tumour staining used to calculate H‐scores for each patient. Cox regression models were used to calculate hazard ratios (HR) and 95{\%} confidence intervals (95{\%} CIs) for overall and cancer‐specific survival, and recurrence‐free survival by PTGS2 expression, adjusting for potential confounders. Patients were followed up for a mean of 3.0 (SD 1.8) years. The PTGS2 expression cut‐off value was determined using the median H‐score of the cohort (270/300). High (n=79), compared to low (n=56), PTGS2 expression was associated with improved cancer‐specific survival (adjusted HR 0.56, 95{\%} CI 0.33‐0.94; p=0.03). PTGS2 expression was not significantly associated with recurrence‐free survival (adjusted HR 0.85, 95{\%} CI 0.52‐1.38; p=0.51).ConclusionsHigh PTGS2 expression in oesophageal adenocarcinoma tissue was associated with improved overall and cancer‐specific survival, contrasting previous evidence. As this is the first study of its kind to include patients who had undergone neoadjuvant chemotherapy further studies are needed to clarify these associations.",
    keywords = "biomarker, epidemiology, oesophageal cancer, PTGS2 expression, Survival",
    author = "Andrew Spence and James Trainor and Una McMenamin and Richard Turkington and Stephen McQuaid and Victoria Bingham and Jacqueline James and Manuel Salto-Tellez and Damian McManus and Brian Johnston and Christopher Cardwell and Helen Coleman",
    year = "2018",
    month = "11",
    day = "8",
    doi = "10.1111/his.13786",
    language = "English",
    pages = "1--24",
    journal = "Histopathology",
    issn = "0309-0167",
    publisher = "Wiley-Blackwell",

    }

    RIS

    TY - JOUR

    T1 - High PTGS2 expression in post neoadjuvant chemotherapy treated oesophageal adenocarcinoma is associated with improved survival: a population-based cohort study

    AU - Spence, Andrew

    AU - Trainor, James

    AU - McMenamin, Una

    AU - Turkington, Richard

    AU - McQuaid, Stephen

    AU - Bingham, Victoria

    AU - James, Jacqueline

    AU - Salto-Tellez, Manuel

    AU - McManus, Damian

    AU - Johnston, Brian

    AU - Cardwell, Christopher

    AU - Coleman, Helen

    PY - 2018/11/8

    Y1 - 2018/11/8

    N2 - AimsHigh prostaglandin endoperoxide synthase‐2 (PTGS2) enzyme expression in oesophageal adenocarcinoma has been shown to independently predict poor prognosis, however evidence is inconsistent. We investigated the association between PTGS2 expression and prognosis in patients with oesophageal adenocarcinoma.Methods and resultsA cohort of 135 patients with oesophageal adenocarcinoma who received neoadjuvant chemotherapy and surgery from 2004 to 2012 was identified in the Northern Ireland Cancer Centre. Tissue microarrays were created in the Northern Ireland Biobank, sampling triplicate cores from each tumour. Immunohistochemical PTGS2 expression was scored by two independent assessors with intensity and proportion of tumour staining used to calculate H‐scores for each patient. Cox regression models were used to calculate hazard ratios (HR) and 95% confidence intervals (95% CIs) for overall and cancer‐specific survival, and recurrence‐free survival by PTGS2 expression, adjusting for potential confounders. Patients were followed up for a mean of 3.0 (SD 1.8) years. The PTGS2 expression cut‐off value was determined using the median H‐score of the cohort (270/300). High (n=79), compared to low (n=56), PTGS2 expression was associated with improved cancer‐specific survival (adjusted HR 0.56, 95% CI 0.33‐0.94; p=0.03). PTGS2 expression was not significantly associated with recurrence‐free survival (adjusted HR 0.85, 95% CI 0.52‐1.38; p=0.51).ConclusionsHigh PTGS2 expression in oesophageal adenocarcinoma tissue was associated with improved overall and cancer‐specific survival, contrasting previous evidence. As this is the first study of its kind to include patients who had undergone neoadjuvant chemotherapy further studies are needed to clarify these associations.

    AB - AimsHigh prostaglandin endoperoxide synthase‐2 (PTGS2) enzyme expression in oesophageal adenocarcinoma has been shown to independently predict poor prognosis, however evidence is inconsistent. We investigated the association between PTGS2 expression and prognosis in patients with oesophageal adenocarcinoma.Methods and resultsA cohort of 135 patients with oesophageal adenocarcinoma who received neoadjuvant chemotherapy and surgery from 2004 to 2012 was identified in the Northern Ireland Cancer Centre. Tissue microarrays were created in the Northern Ireland Biobank, sampling triplicate cores from each tumour. Immunohistochemical PTGS2 expression was scored by two independent assessors with intensity and proportion of tumour staining used to calculate H‐scores for each patient. Cox regression models were used to calculate hazard ratios (HR) and 95% confidence intervals (95% CIs) for overall and cancer‐specific survival, and recurrence‐free survival by PTGS2 expression, adjusting for potential confounders. Patients were followed up for a mean of 3.0 (SD 1.8) years. The PTGS2 expression cut‐off value was determined using the median H‐score of the cohort (270/300). High (n=79), compared to low (n=56), PTGS2 expression was associated with improved cancer‐specific survival (adjusted HR 0.56, 95% CI 0.33‐0.94; p=0.03). PTGS2 expression was not significantly associated with recurrence‐free survival (adjusted HR 0.85, 95% CI 0.52‐1.38; p=0.51).ConclusionsHigh PTGS2 expression in oesophageal adenocarcinoma tissue was associated with improved overall and cancer‐specific survival, contrasting previous evidence. As this is the first study of its kind to include patients who had undergone neoadjuvant chemotherapy further studies are needed to clarify these associations.

    KW - biomarker

    KW - epidemiology

    KW - oesophageal cancer

    KW - PTGS2 expression

    KW - Survival

    UR - http://www.scopus.com/inward/record.url?scp=85060587951&partnerID=8YFLogxK

    U2 - 10.1111/his.13786

    DO - 10.1111/his.13786

    M3 - Article

    SP - 1

    EP - 24

    JO - Histopathology

    T2 - Histopathology

    JF - Histopathology

    SN - 0309-0167

    ER -

    Download

    Download as: RIS